// App-Quantinova.ai

: Mepolizumab for severe eosinophilic asthma: a comparison of efficacy in children, adolescents, and adults

Researchers

Presenter

  • Atul Gupta

Principal Investigators

  • Jonathan Steinfeld

  • Robert Price

  • Jay Azmi

  • Eric Bradford

  • Steven Yancey

Medical Centers

  • Department of Paediatric Respiratory Medicine, King’s College Hospital & King’s College London, London, United Kingdom,

  • Respiratory TAU & Flexible Discovery Unit, GSK, Philadelphia, PA, United States,

  • Clinical Statistics, GSK, Stevenage, Hertfordshire, United Kingdom,

  • Respiratory Therapeutic Area, GSK, Uxbridge, United Kingdom,

  • Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, United States.

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Mepolizumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • NA

Study Id's

  • NCT01000506

  • NCT01691521

  • NCT02281318

  • NCT01691508

  • NCT02377427

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved